We are live on ! Find out more
ELI

ELITE PHARMACEUTICAL
ELI

Delisted

ELI was delisted on the 20th of May, 2009.

Back to rankings

4 hedge funds and large institutions have $156K invested in ELITE PHARMACEUTICAL in 2015 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

54% more capital invested

Capital invested by funds: $101K → $156K (+$54.7K)

20% less funds holding

Funds holding: 5 → 4 (-1)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
4
Holders Change
-1
Holders Change %
-20%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GA
Geneva Advisors
Illinois
+$941

Top Sellers

Rank Fund Capital Flow
1
GIA
Guyasuta Investment Advisors
Pennsylvania
-$13K
Name Holding Trade Value Shares
Change 		Change in
Stake
GA
1
Geneva Advisors
Illinois
$120K +$941 +2,300 +0.8%
JAFL
2
Jay A. Fishman Ltd
Michigan
$24.5K – – –
PCA
3
Personal Capital Advisors
California
$10K – – –
WRM
4
Westport Resources Management
Connecticut
$1K – – –
GIA
5
Guyasuta Investment Advisors
Pennsylvania
– -$13K -60,000 Closed

ELI Hedge Fund Activity: Q4 2015 in Review

4 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in ELITE PHARMACEUTICAL (ELI) for Q4 2015, worth a combined $156K — up 54% from $101K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of ELI and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.

The largest buyer was Geneva Advisors, adding an estimated $941. The largest seller was Guyasuta Investment Advisors, exiting entirely with an estimated $13K sold.

  • 4 institutional investors held ELITE PHARMACEUTICAL (ELI) as of Q4 2015, down from 5 in Q3 2015.
  • Funds reported $156K of ELITE PHARMACEUTICAL stock for Q4 2015, up 54% quarter-over-quarter.
  • 0 funds opened new ELITE PHARMACEUTICAL positions in Q4 2015 and 1 closed out, a net change of -1 holder.
  • The largest ELITE PHARMACEUTICAL buyer in Q4 2015 was Geneva Advisors, an estimated $941 added.
  • The largest ELITE PHARMACEUTICAL seller in Q4 2015 was Guyasuta Investment Advisors, an estimated $13K sold.

Based on aggregated 13F filings for Q4 2015.